We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DENTSPLY SIRONA (XRAY) to Post Q3 Earnings: What's in Store?
Read MoreHide Full Article
DENTSPLY SIRONA Inc. (XRAY - Free Report) is scheduled to release third-quarter 2020 results on Nov 5, before the opening bell.
In the last reported quarter, the company delivered a negative earnings surprise of 500%.
Q3 Estimates
For the third quarter, the Zacks Consensus Estimate for revenues is pegged at $825.6 million, indicating a decline of 14.2% from the year-ago quarter. The consensus mark for earnings stands at 26 cents per share, suggesting a decline of 54.4% from the prior-year quarter.
Factors to Note
DENTSPLY SIRONA’s Consumables segment is likely to have witnessed decline in revenues in the third quarter. The weak performance can be attributed to fall in organic sales resulting from lower demand across all three regions due to lower visits by dentists and customers and procedures on account of the COVID-19 pandemic.
Moreover, the company’s Technology & Equipment segment’s third-quarter results are likely to reflect weak performance across all its products categories, equipment and instruments, and implants owing to the pandemic.
The company’s CAD/CAM is a dental imaging platform and a significant presence in global dental markets. Product launches and innovation in this area might have driven CAD/CAM sales in the to-be-reported quarter. This, in turn, is likely to have contributed to the company’s third-quarter performance in the United States.
However, the impact of the ongoing pandemic may have weighed on the company’s dental imaging platform’s results in the to-be-reported quarter.
Nonetheless, DENTSPLY SIRONA’s Primescan — a digital impression scanner, and Primemill, another addition to the CEREC product portfolio in January, are likely to have positively impacted the company’s third-quarter performance.
The company’s growth strategy has been focused on product innovation, and research and development (R&D), which may have benefited the company’s third-quarter performance. Apart from this, solid track record of innovation and a dedicated, passionate workforce are likely to have contributed to the to-be-reported quarter’s performance.
However, DENTSPLY SIRONA’s significant international presence may have weighed on the company’s third-quarter performance. Foreign exchange headwind is likely to get reflected in the to-be-reported quarter’s results.
What Our Quantitative Model Suggests
Per our proven model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is the case here as you will see.
Earnings ESP: DENTSPLY SIRONA has an Earnings ESP of +12.03%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: DENTSPLY SIRONA carries a Zacks Rank #3.
Other Stocks Worth a Look
Here are some other medical stocks worth considering as these too have the right combination of elements to post an earnings beat this quarter.
GW Pharmaceuticals plc has an Earnings ESP of +9.65% and a Zacks Rank of 3.
Cardinal Health, Inc. (CAH - Free Report) has an Earnings ESP of +3.40% and a Zacks Rank of 2.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
DENTSPLY SIRONA (XRAY) to Post Q3 Earnings: What's in Store?
DENTSPLY SIRONA Inc. (XRAY - Free Report) is scheduled to release third-quarter 2020 results on Nov 5, before the opening bell.
In the last reported quarter, the company delivered a negative earnings surprise of 500%.
Q3 Estimates
For the third quarter, the Zacks Consensus Estimate for revenues is pegged at $825.6 million, indicating a decline of 14.2% from the year-ago quarter. The consensus mark for earnings stands at 26 cents per share, suggesting a decline of 54.4% from the prior-year quarter.
Factors to Note
DENTSPLY SIRONA’s Consumables segment is likely to have witnessed decline in revenues in the third quarter. The weak performance can be attributed to fall in organic sales resulting from lower demand across all three regions due to lower visits by dentists and customers and procedures on account of the COVID-19 pandemic.
Moreover, the company’s Technology & Equipment segment’s third-quarter results are likely to reflect weak performance across all its products categories, equipment and instruments, and implants owing to the pandemic.
The company’s CAD/CAM is a dental imaging platform and a significant presence in global dental markets. Product launches and innovation in this area might have driven CAD/CAM sales in the to-be-reported quarter. This, in turn, is likely to have contributed to the company’s third-quarter performance in the United States.
DENTSPLY SIRONA Inc. Price and EPS Surprise
DENTSPLY SIRONA Inc. price-eps-surprise | DENTSPLY SIRONA Inc. Quote
However, the impact of the ongoing pandemic may have weighed on the company’s dental imaging platform’s results in the to-be-reported quarter.
Nonetheless, DENTSPLY SIRONA’s Primescan — a digital impression scanner, and Primemill, another addition to the CEREC product portfolio in January, are likely to have positively impacted the company’s third-quarter performance.
The company’s growth strategy has been focused on product innovation, and research and development (R&D), which may have benefited the company’s third-quarter performance. Apart from this, solid track record of innovation and a dedicated, passionate workforce are likely to have contributed to the to-be-reported quarter’s performance.
However, DENTSPLY SIRONA’s significant international presence may have weighed on the company’s third-quarter performance. Foreign exchange headwind is likely to get reflected in the to-be-reported quarter’s results.
What Our Quantitative Model Suggests
Per our proven model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is the case here as you will see.
Earnings ESP: DENTSPLY SIRONA has an Earnings ESP of +12.03%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: DENTSPLY SIRONA carries a Zacks Rank #3.
Other Stocks Worth a Look
Here are some other medical stocks worth considering as these too have the right combination of elements to post an earnings beat this quarter.
Zimmer Biomet Holdings, Inc. (ZBH - Free Report) has an Earnings ESP of +4.10% and a Zacks Rank of 3. You can see the complete list of today’s Zacks #1 Rank stocks here.
GW Pharmaceuticals plc has an Earnings ESP of +9.65% and a Zacks Rank of 3.
Cardinal Health, Inc. (CAH - Free Report) has an Earnings ESP of +3.40% and a Zacks Rank of 2.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>